GKGeorge Kritikos

George Kritikos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


George Kritikos has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synergistic activity of rifampicin and polymyxin B against intracellular Gram-negative ESKAPE pathogens involves bacterial membrane alterations and enhanced oxidative damages

    by Vallo Varik, Gang Wang, George Kritikos, Manuel Banzhaf, Emilien Drouot, Alexandra Koumoutsi, Françoise Van Bambeke

    Antibiotic-resistant bacteria, particularly the ESKAPE ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens, pose a major public health threat. Their ability to reside inside cells contributes to their persistence and resistance. Combining rifampicin with polymyxins is a much-discussed approach against multidrug-resistant Gram-negative bacterial infections. We therefore evaluated a combination of polymyxin B and rifampicin against Gram-negative clinical isolates in extracellular and intracellular in vitro models of infection. The combination was synergistic against intra- and extra-cellular forms of P. aeruginosa, A. baumannii, E. coli , and K. pneumoniae . This synergy was enhanced in an acidic environment resembling the host vacuole where intracellular bacteria reside. The combination remained synergistic against rifampicin and polymyxin B-resistant P. aeruginosa . To reveal the molecular underpinnings of the synergy, we used reverse genetics to identify and describe P. aeruginosa mutants more susceptible to the combination. They show altered membrane properties and more pronounced oxidative damage when exposed to the combination. This work sheds a new light on the mechanisms of the synergy between rifampicin and polymyxins, demonstrates its applicability to Gram-negative ESKAPE pathogens, including when residing intracellularly. Overall, the data suggest that repurposing rifampicin with polymyxin B can effectively target hard-to-eradicate intracellular bacteria.


  • Open Access

    Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics

    by Nazgul Sakenova, Elisabetta Cacace, Askarbek Orakov, Florian Huber, Vallo Varik, George Kritikos, Jan Michiels, Peer Bork, Pascale Cossart, Camille V. Goemans, et al.

    By acquiring or evolving resistance to one antibiotic, bacteria can become cross-resistant to a second antibiotic, which further limits therapeutic choices. In the opposite scenario, initial resistance leads to collateral sensitivity to a second antibiotic, which can inform cycling or combinatorial treatments. Despite their clinical relevance, our knowledge of both interactions is limited. We used published chemical genetics data of the Escherichia coli single-gene deletion library in 40 antibiotics and devised a metric that discriminates between known cross-resistance and collateral-sensitivity antibiotic interactions. Thereby we inferred 404 cases of cross-resistance and 267 of collateral-sensitivity, expanding the number of known interactions by over threefold. We further validated 64/70 inferred interactions using experimental evolution. By identifying mutants driving these interactions in chemical genetics, we demonstrated that a drug pair can exhibit both interactions depending on the resistance mechanism. Finally, we applied collateral-sensitive drug pairs in combination to reduce antibiotic-resistance development in vitro.


  • Open Access

    Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics

    by Nazgul Sakenova, Elisabetta Cacace, Askarbek Orakov, Florian Huber, Vallo Varik, George Kritikos, Jan Michiels, Peer Bork, Pascale Cossart, Camille Goemans, et al.

    By acquiring or evolving resistance to one antibiotic, bacteria can become resistant to a second one, due to shared underlying mechanisms. This is called cross-resistance (XR) and further limits therapeutic choices. The opposite scenario, in which initial resistance leads to sensitivity to a second antibiotic, is termed collateral sensitivity (CS) and can inform cycling or combinatorial treatments. Despite their clinical relevance, our current knowledge of such interactions is limited, mostly due to experimental constraints in their assessment and lack of understanding of the underlying mechanisms. To fill this gap, we used published chemical genetic data on the impact of all Escherichia coli non-essential genes on resistance/sensitivity to 40 antibiotics, and devised a metric that robustly discriminates between known XR and CS antibiotic interactions. This metric, based on chemical genetic profile (dis)similarity between two drugs, allowed us to infer 404 XR and 267 CS interactions, thereby expanding the number of known interactions by more than 3-fold – including reclassifying 116 previously reported interactions. We benchmarked our results by validating 55 out of 59 inferred interactions via experimental evolution. By identifying mutants driving XR and CS interactions in chemical genetics, we recapitulated known and uncovered previously unknown mechanisms, and demonstrated that a given drug pair can exhibit both interactions depending on the resistance mechanism. Finally, we applied CS drug pairs in combination to reduce antibiotic resistance development in vitro. Altogether, our approach provides a systematic framework to map XR/CS interactions and their mechanisms, paving the way for the development of rationally-designed antibiotic combination treatments.


  • Open Access

    ChemGAPP; A Package for Chemical Genomics Analysis and Phenotypic Profiling

    by Hannah M. Doherty, George Kritikos, Marco Galardini, Manuel Banzhaf, Danesh Moradigaravand

    High-throughput chemical genomic screens produce informative datasets, providing valuable insights into unknown gene function on a genome-wide level. However, there is currently no comprehensive analytic package publicly available. We developed and benchmarked ChemGAPP to bridge this gap. ChemGAPP allows integration of various steps in a streamlined and user-friendly format, including rigorous quality control measures to curate screening data. ChemGAPP provides three sub-packages for different chemical-genomic screens: ChemGAPP Big for handling large-scale high-throughput screens; ChemGAPP Small, designed for small-scale screen analysis and ChemGAPP GI for genetic interaction screen analysis. ChemGAPP is available at https://github.com/HannahMDoherty/ChemGAPP .

  • Top Cited Papers

    Bacterial retrons encode phage-defending tripartite toxin–antitoxin systems

    by Jacob Bobonis, Karin Mitosch, André Mateus, Nicolai Karcher, George Kritikos, Joel Selkrig, Matylda Zietek, Vivian Monzon, Birgit Pfalz, Sarela Garcia-Santamarina, et al.

    Retrons are prokaryotic genetic retroelements, encoding a reverse transcriptase (RT) that produces multi-copy single-stranded DNA (msDNA1). Despite decades of research on msDNA biosynthesis2, the function and physiological role of retrons remained elusive. We show that Retron-Sen2 of Salmonella Typhimurium encodes an accessory toxin protein, which we rename RcaT. RcaT is neutralized by the RT-msDNA antitoxin complex, becoming active upon perturbations of msDNA biosynthesis. The RT is required for binding to RcaT, and the msDNA for enabling the antitoxin activity. The highly prevalent RcaT-containing retron family constitutes a new type of tripartite DNA-containing toxin/antitoxin systems (TAs). To understand their physiological role, we developed TAC/TIC (Toxin Activation/Inhibition Conjugation), a high-throughput reverse genetics approach that identifies the elusive molecular triggers and blockers of TAs. By applying TAC/TIC to Retron-Sen2 we identified multiple such proteins of phage origin. We demonstrate that phage-related triggers directly modify the msDNA, thereby activating RcaT and inhibiting bacterial growth. In contrast, prophage proteins circumvent retrons by directly blocking RcaT. Consistently, retron-TAs act as abortive-infection anti-phage defense systems, in line with parallel reports3,4. Thus, RcaT-retrons are tripartite DNA-regulated TAs, which use the RT-msDNA complex both as antitoxin and as a sensor of phage protein activities.


  • Open Access

    Phage proteins block and trigger retron toxin/antitoxin systems

    by Jacob Bobonis, Karin Mitosch, André Mateus, George Kritikos, Johanna R. Elfenbein, Mikhail M. Savitski, Helene Andrews-Polymenis, Athanasios Typas

    Bacteria carry dozens of Toxin/Antitoxin systems (TAs) in their chromosomes. Upon growth, the antitoxin is co-expressed and neutralizes the toxin. TAs can be activated and inhibit growth, but when and how this occurs has largely remained enigmatic, hindering our understanding of their physiological roles. We developed TIC/TAC (Toxin Inhibition/Activation Conjugation), a high-throughput reverse genetics approach, to systematically identify molecular blockers and triggers of TAs. By applying TIC/TAC to a tripartite TA, the retron-Sen2 of Salmonella Typhimurium, we have identified multiple blockers and triggers of phage origin. We demonstrate that diverse phage functionalities are sensed by the DNA-part of the antitoxin and ultimately activate the retron toxin. Phage-origin proteins can circumvent activation by directly blocking the toxin. Some identified triggers and blockers also act on an E. coli retron-TA, Eco9. We propose that retron-TAs act as abortive-infection anti-phage defense systems, and delineate mechanistic principles by which phages trigger or block them.


  • Top Cited Papers
    Open Access

    Construction and Analysis of Two Genome-Scale Deletion Libraries for Bacillus subtilis

    by Byoung-Mo Koo, George Kritikos, Jeremiah D. Farelli, Horia Todor, Kenneth Tong, Harvey Kimsey, Ilan Wapinski, Marco Galardini, Angelo Cabal, Jason M. Peters, et al.


  • Open Access

    A tool named Iris for versatile high-throughput phenotyping in microorganisms

    by George Kritikos, Manuel Banzhaf, Lucia Herrera-Dominguez, Alexandra Koumoutsi, Morgane Wartel, Matylda Zietek, Athanasios Typas

    Advances in our ability to systematically introduce and track controlled genetic variance in microorganisms have, in the past decade, fuelled high-throughput reverse genetics approaches. When coupled to quantitative readouts, such approaches are extremely powerful at elucidating gene function and providing insights into the underlying pathways and the overall cellular network organization. Yet, until now, all efforts to quantify microbial macroscopic phenotypes have been restricted to monitoring growth in a small number of model microorganisms. We have developed an image analysis software named Iris, which allows for systematic exploration of a number of orthogonal-to-growth processes, including biofilm formation, colony morphogenesis, envelope biogenesis, sporulation and reporter activity. In addition, Iris provides more sensitive growth measurements than currently available software and is compatible with a variety of different microorganisms, as well as with endpoint or kinetic data. We used Iris to reanalyse existing chemical genomics data in Escherichia coli and to perform proof-of-principle screens on colony biofilm formation and morphogenesis of different bacterial species and the pathogenic fungus Candida albicans. We thereby recapitulated existing knowledge but also identified a plethora of additional genes and pathways involved in both processes.


  • Open Access

    A Chemical-Genomic Screen of Neglected Antibiotics Reveals Illicit Transport of Kasugamycin and Blasticidin S

    by Anthony L. Shiver, Hendrik Osadnik, George Kritikos, Bo Li, Nevan Krogan, Athanasios Typas, Carol A. Gross

    Fighting antibiotic resistance requires a deeper understanding of the genetic factors that determine the antibiotic susceptibility of bacteria. Here we describe a chemical-genomic screen in Escherichia coli K-12 that was designed to discover new aspects of antibiotic resistance by focusing on a set of 26 antibiotics and other stresses with poorly characterized mode-of-action and determinants of resistance. We show that the screen identifies new resistance determinants for these antibiotics including a common signature from two antimicrobials, kasugamycin and blasticidin S, used to treat crop diseases like rice blast and fire blight. Following this signature, we further investigated the mechanistic basis for susceptibility to kasugamycin and blasticidin S in E. coli using both genetic and biochemical approaches. We provide evidence that these compounds hijack an overlapping set of peptide ABC-importers to enter the bacterial cell. Loss of uptake may be an underappreciated mechanism for the development of kasugamycin resistance in bacterial plant pathogens. Bacterial species differ in their susceptibility to antibiotics but the reason for these differences remains an open question. Understanding the genetic basis of antibiotic susceptibility will be critical for predicting the efficacy of new antibiotics and possibly finding new antibiotic targets. Here we report a large-scale study that connects bacterial genes to antibiotics, using a set of antibiotics that were chosen to include poorly characterized compounds. We discovered genes that confer resistance to a number of neglected antibiotics, expanding our knowledge of gene function and antibiotic resistance in Escherichia coli K-12. Starting from this large-scale screen, we then investigated how two antibiotics with a common history, kasugamycin and blasticidin S, enter bacterial cells. Both mimic naturally occurring nutrients to trick E. coli into actively bringing them inside. Kasugamycin is used to control microbes that cause agricultural diseases and mutations that reduce uptake like those we describe here may be an underappreciated factor in the development of resistance to kasugamycin.


  • Open Access

    A Genome-Wide Screen for Bacterial Envelope Biogenesis Mutants Identifies a Novel Factor Involved in Cell Wall Precursor Metabolism

    by Catherine Paradis-Bleau, George Kritikos, Katya Orlova, Athanasios Typas, Thomas G. Bernhardt

    The cell envelope of Gram-negative bacteria is a formidable barrier that is difficult for antimicrobial drugs to penetrate. Thus, the list of treatments effective against these organisms is small and with the rise of new resistance mechanisms is shrinking rapidly. New therapies to treat Gram-negative bacterial infections are therefore sorely needed. This goal will be greatly aided by a detailed mechanistic understanding of envelope assembly. Although excellent progress in the identification of essential envelope biogenesis systems has been made in recent years, many aspects of the process remain to be elucidated. We therefore developed a simple, quantitative, and high-throughput assay for mutants with envelope biogenesis defects and used it to screen an ordered single-gene deletion library of Escherichia coli. The screen was robust and correctly identified numerous mutants known to be involved in envelope assembly. Importantly, the screen also implicated 102 genes of unknown function as encoding factors that likely impact envelope biogenesis. As a proof of principle, one of these factors, ElyC (YcbC), was characterized further and shown to play a critical role in the metabolism of the essential lipid carrier used for the biogenesis of cell wall and other bacterial surface polysaccharides. Further analysis of the function of ElyC and other hits identified in our screen is likely to uncover a wealth of new information about the biogenesis of the Gram-negative envelope and the vulnerabilities in the system suitable for drug targeting. Moreover, the screening assay described here should be readily adaptable to other organisms to study the biogenesis of different envelope architectures. Bacteria are surrounded by complex structures called cell envelopes that play an essential role in maintaining cellular integrity. Organisms classified as Gram-negative have especially complicated envelopes that consist of two membranes with a tough cell wall exoskeleton sandwiched between them. This envelope architecture is extremely proficient at preventing drug molecules from entering the cell. Gram-negative bacteria are therefore intrinsically resistant to many antibiotics, limiting the therapeutic options for treating infections caused by these organisms. To reveal new weaknesses in the Gram-negative envelope for drug targeting, we developed a quantitative, high-throughput assay for mutants with envelope biogenesis defects and used it to screen an ordered single-gene deletion library of the model Gram-negative bacterium Escherichia coli. Importantly, the screen implicated 102 genes of previously unknown function as encoding factors that likely participate in envelope biogenesis. As a proof of principle, one of these factors, ElyC (YcbC), was characterized further and shown to play a critical role in the metabolism of the essential lipid carrier used for cell wall synthesis. Further study of ElyC function and that of other factors identified in our screen is likely to reveal novel ways to disrupt the envelope assembly process for therapeutic purposes.